Luo Yongqing, General Manager of Gilead China, is leaving and his successor is in the process of being recruited.

Johanna says Gilead China has grown into an organization of more than 450 people over the past few years with Mr. Luo's help.
the team has successfully launched eight new products in the field of AIDS and viral hepatitis, four of which were successfully added to the national health insurance list last year, and so far they have helped more than 120,000 Chinese patients.
, the Chinese business has become a central pillar of Gilead's global growth strategy.
recently, Rogers has played a significant role in bringing Red West to China for clinical trials and local production.
it is understood that Gilead will immediately start the recruitment of Mr Luo Yongqing's successor.
, Gilead's Senior Vice President of Global Intercontinentals, Jacob Andreose, will temporarily take charge of the China team and business.
, Mr. Luo Yongqing, Mr. Rogers Luo, joined Gilead Sciences in September 2016 as Vice President of Gilead Sciences Global and General Manager of China.
previously served as Vice President of Roche Pharmaceuticals, mr. Luo Yongqing served for Novartis Pharmaceuticals for 10 years before joining Roche, and finally as General Manager of Novartis North China.
joined Gilead, he also gave full play to his experience and talents in market access, business and customer management, which helped to promote Gilead's development in China.
In April 2018, Gilead's hepatitis C star drug Sovaldi was approved in China; in December 2018, Gilead's second-generation Harvoni was approved in China; and Gilead officially opened its China headquarters in Shanghai in 2016 for commercial operations, which could be said to have been formed by Rogers Luo.
.